Mani Mohindru

Directeur Général chez CARDIFF ONCOLOGY, INC. Fortune : 50 502 $ au 31/07/2026

Profil

Dr. Mani Mohindru is a President, Chief Executive Officer & Director at Cardiff Oncology, Inc., an Independent Director at CytomX Therapeutics, Inc. and a Chairman at Roshon Therapeutics, Inc. She is on the Board of Directors at Cardiff Oncology, Inc. and CytomX Therapeutics, Inc. Dr. Mohindru was previously employed as a Chief Executive Officer & Director by Novasenta, Inc., a Chief Executive Officer by CereXis, Inc., a Chief Financial & Strategy Officer by CARA Therapeutics, Inc., a Chief Strategy Officer by Curis, Inc., a Co-Founder by Immtox LLC, a Partner by Axon Healthcare Ltd., a Vice President by Credit Suisse Securities (USA) LLC (Broker), a Managing Director by Capstone Investments, an Analyst by ThinkEquity LLC, and a Research Analyst by UBS Securities LLC.
She also served on the board at SAB Biotherapeutics, Inc. (United States).
She received her undergraduate degree from All India Institute of Medical Sciences, a graduate degree from All India Institute of Medical Sciences and a doctorate degree from Northwestern University.

Détentions connues dans des sociétés publiques

Société	Date	Nombre d'actions	Valorisation	Date de valorisation
CARDIFF ONCOLOGY, INC. 0,08 %	14/07/2026	59 067 ( 0,08 % )	50 502 $	31/07/2026
CYTOMX THERAPEUTICS, INC. -.--%	17/06/2026	0 ( -.--% )	- $	31/07/2026

Postes actifs de Mani Mohindru

Sociétés	Poste	Début
CYTOMX THERAPEUTICS, INC.	Directeur/Membre du Conseil	16/12/2020
CARDIFF ONCOLOGY, INC.	Directeur Général	27/01/2026

Anciens postes connus de Mani Mohindru

Sociétés	Poste	Fin
Novasenta, Inc.	Directeur Général	01/03/2024
SAB Sciences, Inc.	Directeur/Membre du Conseil	01/05/2021
CereXis, Inc.	Directeur Général	01/10/2020
CARA THERAPEUTICS, INC.	Directeur Financier/CFO	20/12/2019
CURIS, INC.	Investor Relations Contact	01/03/2016